Lisata Therapeutics Inc (LTS:0HS8)
$ 3.255 0 (0%) Market Cap: 28.95 Mil Enterprise Value: -14.23 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 37/100

Caladrius Biosciences Inc Provides Update on Phase 2b FREEDOM Trial Conference Call and Webcast Transcript

May 24, 2022 / 12:15PM GMT
Release Date Price: $6.67
Operator

Welcome to the Caladrius Biosciences FREEDOM trial status update conference call. (Operator Instructions) As a reminder, this call is being recorded today, Tuesday, May 24, 2022.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

John D. Menditto
Caladrius Biosciences, Inc. - VP of IR & Corporate Communications

Thank you, operator, and good morning everyone. Welcome to Caladrius' conference call for an update on the status of the FREEDOM trial of XOWNA in coronary microvascular dysfunction. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer and Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer.

Last evening, we issued a press release on the status update which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you've not received this news release or would like to be added to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot